Retour
Xencor Inc (XNCR) Gagner
Graphique du cours de l'action XNCR
XNCR Gagner
Xencor Inc
$11.42
-7.22%
$-0.89
À la fermeture : Mar 27, 16:00:00 GMT-4
$11.2
-1.92%
$-0.22
Post-Marché: Mar 27, 20:00:00 GMT-4
Statistiques clés
Clôture préc.
$12.31
Prix d'ouverture
$12.17
Plage de la journée
$11.2 - $12.4
Plage de 52 semaines
$6.92 - $18.69
Volume
845.9K
Volume moyen
727.8K
Rendement en dividend
--
BPA (TTM)
-1.88
Capitalisation boursière
$821.4M
Qu’est-ce que XNCR ?
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Pasadena, California and currently employs 260 full-time employees. The company went IPO on 2013-12-03. The company has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Fonctionnalités
Ressources
© 2026 Finture Development Limited. Tous droits réservés.